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Abstract
The neuronal dopamine transporter (DAT) is a major determinant of extracellular dopamine (DA) levels and is the primary
target for a variety of addictive and therapeutic psychoactive drugs. DAT is acutely regulated by protein kinase C (PKC)
activation and amphetamine exposure, both of which modulate DAT surface expression by endocytic trafficking. In order to
use live imaging approaches to study DAT endocytosis, methods are needed to exclusively label the DAT surface pool. The
use of membrane impermeant, sulfonated biarsenic dyes holds potential as one such approach, and requires introduction of
an extracellular tetracysteine motif (tetraCys; CCPGCC) to facilitate dye binding. In the current study, we took advantage of
intrinsic proline-glycine (Pro-Gly) dipeptides encoded in predicted DAT extracellular domains to introduce tetraCys motifs
into DAT extracellular loops 2, 3, and 4. [3H]DA uptake studies, surface biotinylation and fluorescence microscopy in PC12
cells indicate that tetraCys insertion into the DAT second extracellular loop results in a functional transporter that maintains
PKC-mediated downregulation. Introduction of tetraCys into extracellular loops 3 and 4 yielded DATs with severely
compromised function that failed to mature and traffic to the cell surface. This is the first demonstration of successful
introduction of a tetracysteine motif into a DAT extracellular domain, and may hold promise for use of biarsenic dyes in live
DAT imaging studies.
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Introduction
DA reuptake mediated by DAT is the primary means for
clearing synaptic DA and terminating dopaminergic neurotrans-
mission [1], [2]. DAT is member of the Na+/Cl2 -dependent
SLC6 symporter gene family and is potently inhibited by addictive
psychostimulants, such as amphetamine and cocaine, as well as by
therapeutic agents such as the NDRI class of antidepressants and
methylphenidate (Ritalin) [3], [4], [5]. Transgenic mouse studies
indicate that DAT is critical in maintaining normal dopaminergic
neurotransmission and synaptic tone, and that even a 50%
reduction in DAT protein (DAT +/2 mice) is sufficient to
significantly alter DA signaling and synaptic stores [6], [7]. Thus,
cellular mechanisms that modulate DAT cell surface expression
are likely to have a significant impact on DA availability and
signaling in the brain.
DAT is acutely downregulated by PKC activation [8], [9] and
amphetamine exposure [10], [11], [12], which markedly
decrease DAT surface levels via endosomal trafficking. While it
is well established DAT surface levels are modulated by
endocytic trafficking, the cellular mechanisms that mediate
DAT trafficking are not well defined. Live cellular imaging is a
highly effective means to reveal cellular trafficking mechanisms
that are not detectable by fixed cell imaging or biochemical
approaches [13], [14]. Recent studies using GFP-tagged DAT
[15] and fluorescently-labeled cocaine analogs [16] have proved
successful in achieving live DAT trafficking images; however,
each approach has inherent limitations. GFP-tagged DAT may
not behave identically to the wildtype DAT, and has the
disadvantage of labeling the entire cellular DAT population,
limiting the ability to examine DAT surface dynamics specifi-
cally. Use of cocaine analogs allows for exclusive labeling of the
DAT surface pool, but may not reflect native DAT trafficking as
cocaine binding has itself been reported to alter DAT surface
expression [17], [18].
The use of biarsenic dyes, such as FlAsH, ReAsH [19] and
SplAsH [20], is another potential means to fluorescently label
proteins for live imaging. In particular, sulfonated versions of these
dyes are membrane impermeant and may be suitable to exclusively
label surface proteins [21]. Biarsenic dyes are not fluorescent in
solution and bind with high affinity to tetracysteine (tetraCys)
motifs, preferably flanking a proline-glycine (Pro-Gly) dipeptide
(CCPGCC) [21]. Upon binding, they become highly fluorescent. In
the current study, we engineered tetraCys motifs flanking existing
extracellular Pro-Gly dipeptide residues encoded in human DAT
(hDAT) at amino acid positions 194, 288 and 387, to use as
potential biarsenic dye labeling sites. Analysis of these DATmutants
reveals that inserting a tetraCys site into DAT extracellular loop 2
(EL2) is well tolerated by DAT, and yields a functional transporter
that retains sensitivity to PKC activation, whereas insertion of
tetraCys into either extracellular loop 3 or 4 (EL3, EL4) perturbs
DAT biosynthesis and trafficking to the cell surface.
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Methods
Constructs and Mutagenesis
TetraCys motifs flanking existing extracellular Pro-Gly residues
were engineered into EL2, EL3 or EL4 DAT extracellular loops
by mutating the two residues upstream and downstream of the
Pro-Gly residues into cysteines. The amino acids mutated to
cysteines were: EL2: 192–193/196–197; EL3: 286–287/290–291;
EL4 385–386/389–390. hDAT pcDNA3.1(+) was mutated using
the QuikChange Mutagenesis kit (Stratagene). The following
mutagenic primers spanning the indicated hDAT cDNA regions
were used:
EL2-CCPGCC (577–627)
59CCCCAACTGCTCGGATTGCTGTCCTGGTTGCTGC-
AGTGGAGACAGCTCGG39 (sense),
59CCGAGCTGTCTCCACTGCAGCAACCAGGACAGCA-
ATCCGAGCAGTTGGGG39(antisense);
EL3-CCPGCC (860–907)
59CTCCTGCGTGGGGTCTGCTGCCCTGGATGCTGT-
GACGGCATCAGAGCA39 (sense),
59TGCTCTGATGCCGTCACAGCATCCAGGGCAGCAG-
ACCCCACGCAGGAG39(antisense);
EL4-CCPGCC (1156–1205)
59 CGGGGACGTGGCCAAGTGCTGCCCAGGGTGCTG-
CTTCATCATCTACCCGG 39 (sense),
59CCGGGTAGATGATGAAGCAGCACCCTGGGCAGCA-
CTTGGCCACGTCCCCG39(antisense).
Mutations were confirmed by sequencing (UMASS Medical
School Nucleic Acid Facility) and mutagenic regions were
subcloned back into the parental hDAT cDNA using the following
restriction enzymes: PflMI/BstEII (EL2-CCPGCC), PflMI/ClaI
(EL3-CCPGCC), BstEII/ClaI (EL4-CCPGCC).
Cell Culture and Transfections
PC12 cells were from ATCC as previously described [22] and
were cultured at 10% CO2 in high glucose DMEM supplemented
with 5% horse serum, 5% bovine calf serum, 2 mM glutamine and
102 U/ml penicillin-streptomycin. Cells were removed from the
cultureware by spraying media directly onto the growth surface
and triturating. Cells were transiently transfected either with
Lipofectamine 2000 (Invitrogen), according to the manufacture’s
instructions, or by electroporation as previously described [23].
Briefly, 1.26107 cells were collected by centrifugation and
resuspended in 0.75 ml electroporation buffer (137 mM NaCl,
5.0 mM KCl, 0.7 mM Na2HPO4, 6.0 mM glucose, 20 mM
HEPES, pH 7.05) and were mixed with 18.2 mg of the indicated
plasmids. Cells were electroporated at 300 mV, 500 mF, with an
exponential decay protocol, using a GenePulser Xcell unit (Biorad,
Hercules, CA) with a CE module and 4.0 mm cuvettes. Following
30 min recovery in PC12 media containing 3 mM EGTA, cells
were plated onto poly-D-lysine coated plates as indicated. All
transfected cells were assayed 48 hrs post-transfection.
Surface Biotinylation and Immunoblotting
Cells were seeded in 6 well plates coated with 0.5 mg/ml poly-
D-lysine 48 hours prior to performing assays. For surface
biotinylation, cells were washed with phosphate buffered saline
supplemented with 1.5 mM MgCl2, 0.2 mM CaCl2 (PBS
2+) and
surface proteins were covalently labeled biotin by incubating
2615 min, 4uC with freshly prepared 1.0 mg/ml sulfo-NHS-SS-
biotin (Pierce) prepared in PBS2+. Residual biotinylation reagent
was quenched by washing cells with and incubating 26159, 4uC in
PBS2+, 100 mM glycine. Cells were lysed in RIPA buffer (10 mM
Tris, pH 7.4, 150 mM NaCl, 1.0 mM EDTA, 0.1% SDS, 1.0%
Triton X 100, 1.0% sodium deoxycholate) containing protease
inhibitors (1.0 mM PMSF, 1.0 mg/ml each leupeptin, aprotinin
and pepstatin), 20 min, 4uC, cellular debris was cleared by
centrifugation and protein concentrations were determined with
the BCA protein assay (Pierce). Surface (biotinylated) proteins
were separated from intracellular (non-biotinylated) proteins by
streptavidin batch affinity chromatography using streptavidin-
coupled agarose beads (Pierce), incubating overnight, 4uC with
rotation. Non-biotinylated proteins in the supernatants were
removed and concentrated by spin filtration using columns with
30 kDa molecular weight cutoff (Millipore). Beads bound to
biotinylated proteins were washed three times with RIPA buffer
and bound proteins were eluted in 2x Laemmli sample buffer by
rotating 30 min, 25uC. Samples were separated on 10% SDS-
PAGE gels and were transferred onto nitrocellulose for 1 hour,
100 V, 4uC. Blots were blocked with 5% nonfat dry milk in PBS/
0.1% Tween-20 (PBS-T), 45 min, 25uC, and incubated with rat
anti-DAT antibody (MAB369, Chemicon, 1:1000) overnight, 4uC.
Blots were washed with PBS-T and incubated with HRP-
conjugated goat anti-rat antibody (Santa Cruz, 1:5000), 459,
25uC, following by washing in PBS-T. Blots were developed with
Supersignal Dura (Pierce) and immunoreactive bands were
detected with a VersaDoc imaging station (Bio-Rad). Non-
saturating bands were quantified using Quantity One software
and results were analyzed using GraphPad Prism software.
Mature:immature protein ratios were calculated by summing
mature band (90 kDa) densities in surface and intracellular
fractions, and dividing by the immature band (56 kDa) density
in the intracellular fraction.
Immunocytochemistry and Microscopy
Transfected cells were seeded on glass coverslips coated with
1.0 mg/ml poly-D-lysine 48 hours prior to fixation and labeling.
Cells were treated as indicated, rinsed in PBS and fixed in 4%
paraformaldehyde prepared in PBS, 10 min, 25uC. Cells were
blocked and permeabilized by incubating in blocking solution
(PBS, 1% IgG/Protease-free BSA, 5% goat serum, 0.2% Triton-
X-100), 309, 25uC, followed by incubation with rat anti-DAT
antibody (1:2000 in blocking solution), 45 min, 25uC. Cells were
washed with PBS and incubated with Alexa594-conjugated goat
anti-rat antibody (1:5000, Molecular Probes), 45 min, 25uC. Cells
were washed with PBS, dried and mounted on glass slides with
ProLong Gold (Molecular Probes). Immunoreactive cells were
visualized as previously described [24] with a Zeiss Axiovert
200 M microscope using a 63X, 1.4 N.A. oil immersion objective
and 0.4 mm optical sections were captured through the z-axis with
a Retiga-1300R cooled CCD camera (Qimaging) using Slidebook
4.0 software (Intelligent Imaging Innovations). Z- stacks were
deconvolved with a constrained iterative algorithm using mea-
sured point spread functions for each fluorescent channel using
Slidebook 4.0 software. All images shown are single 0.4 mm planes
through the center of each cell.
[3H]DA Uptake Assays
Transfected cells were seeded onto 24 well plates coated with
0.5 mg/ml poly-D-lysine and [3H]DA uptake was measured
48 hours post transfection as previously reported [23], [25].
Briefly, cells were rinsed and pre-incubated in KRH buffer
(120 mM NaCl, 4.7 mM KCl, 2.2 mM CaCl2, 1.2 mM MgSO4,
1.2 mM KH2PO4, 0.18% glucose, 10 mM HEPES, pH 7.4) at
DA Transporter Tetracysteines
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either for 37uC for 30 min with the indicated drugs. 100 nM
desipramine was included in all wells to block endogenous NET
activity. Uptake was initiated by adding 1.0 mM [3H]DA
(dihydroxyphenylethylamine 3,4-[ring-2,5,6,-3H], Perkin Elmer)
containing 1025 M pargyline and 1025 M ascorbic acid. Assays
proceeded for 10 min (37uC) and were terminated by rapidly
washing cells with ice-cold KRH buffer. Cells were solubilized in
scintillation fluid and accumulated radioactivity was determined
by liquid scintillation counting in a Wallac Microbeta scintillation
plate counter. Non-specific uptake was defined in the presence of
10 mM GBR12909 and averaged ,5% of total counts measured.
Data analysis was performed using Microsoft Excel and GraphPad
Prism Software.
Results
Protein labeling with biarsenic dyes requires the presence of a
tetraCys motif, optimally flanking a Pro-Gly dipeptide. As
depicted in Figure 1, DAT encodes three predicted extracellular
Pro-Gly sequences at residues 194, 288 and 387. We took
advantage of these intrinsic Pro-Gly residues and mutated the 2
upstream and downstream residues to cysteines to generate three
DAT constructs with CCPGCC sequences in either extracellular
loops 2, 3 or 4 (termed DAT EL2-CCPGCC, EL3-CCPGCC and
EL4-CCPGCC, respectively). We first tested whether the mutant
DATs retained DA transport function as compared to wildtype
DAT. As seen in Figure 2A, all three tetraCys mutants exhibited
significantly reduced DA uptake as compared to wildtype DAT
(p,.01). However, DAT-EL2-CCPGCC retained 63.5% of wild-
type activity, which was significantly greater than both DAT-EL3-
CCPGCC and DAT-EL4-CCPGCC (p,.001). We next tested
whether any of the DAT tetraCys mutants were capable of
undergoing PKC-mediated downregulation. Following treatment
with 100 nM PMA, 309, 37uC, wildtype DAT function decreased
by 30.762.3% (Fig. 2B). Similarly, PKC activation decreased
DAT-EL2-CCPGCC activity by 29% (Not significantly different
from wild type, p= 0.77, Student’s t test, n = 3). In contrast, PKC
activation had no effect on either DAT-EL3-CCPGCC or DAT-
EL4-CCPGCC (Fig. 2B). These data suggest that introduction of a
tetraCys motif into the DAT EL2 results in a functional DAT that
undergoes PKC-mediated downregulation, whereas conversion of
residues in EL3 and EL4 is not well tolerated by DAT.
Figure 1. Schematic of DAT with target sites for tetracysteine
mutagenesis. Top: DAT model. Asteriks indicate extracellular Pro-Gly
residues targeted for tetracysteine mutagenesis. Bottom: DAT sequenc-
es spanning across the Pro-Gly tetracysteine target sites. Pro-Gly
dipeptides are highlighted in the shaded boxes.
doi:10.1371/journal.pone.0009113.g001
Figure 2. DA uptake and PKC-mediated downregulation are
preserved when a tetracysteine motif is introduced into EL2,
but not EL3 or EL4. DA uptake assay. Cells were transfected as
described in Methods and [3H]DA uptake was assessed 48 hours post
transfection. A. Introduction of tetracysteine motifs decreases DA
uptake. Data are expressed as % wildtype activity 6S.E.M. *Significantly
different from wildtype (p,.01, One-way ANOVA with Tukey’s multiple
comparison test, n = 3), **Significantly different from EL2-CCPGCC DAT
(p,.001, One-way ANOVA with Tukey’s multiple comparison test, n = 3).
B. EL2-CCPGCC DAT is acutely downregulated by PKC activation,
whereas EL3- and EL4-CCPGCC are not. Cells were treated with either
vehicle or 100 nM PMA, 30 min, 37uC and [3H]DA uptake was measured.
Data are expressed as % vehicle-treated DA uptake 6S.E.M. for each
construct. *Significantly different from vehicle treated (p,.05, Student’s
t test, n = 3), **significantly different from vehicle treated (p,.02,
Student’s t test, n = 3).
doi:10.1371/journal.pone.0009113.g002
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We next used cell surface biotinylation to test whether the
tetracysteine DATs exhibited maturation and cell surface
expression comparable to wildtype DAT. As seen in Figure 3A,
surface and intracellular proteins are readily detectable for both
wildtype and EL2-CCPGCC DATs, and no significant difference
between the %total mature DAT on the cell surface was detected
(Fig. 3B, 48.166.7% (wildtype) vs. 49.065.4% (EL2-CCPGCC),
p = .92, Student’s t test, n = 4). In contrast, neither EL3 nor EL4
were detected at the cell surface, nor was any mature protein
detected, suggesting that these mutants fail to progress through the
biosynthetic pathway (Fig. 3C). We also measured the ratios of
mature (90 kDa) to immature (56 kDa) DAT as an index of how
readily EL2-CCPGCC DAT progresses through the biosynthetic
pathway. Wildtype DAT exhibited mature:immature protein ratio
of 1.6660.22, whereas EL2-CCPGCC DAT had a trend for less
mature:immature protein (0.996.17), but which was not signifi-
cantly different from wildtype (p= .07, Student’s t test, n = 4),
suggesting that EL2-CCPGCC DAT is processed through the
biosynthetic pathway comparably to wildtype DAT.
We next used fluorescence microscopy to examine the cellular
distribution of the tetracysteine-tagged DATs as compared to
wildtype DAT in transiently transfected PC12 cells. Wildtype
DAT staining presented as an intense ring at the cell perimeter,
and PKC activation resulted in robust DAT redistribution to
intracellular puncta (Fig. 4A). Similarly, EL2-CCPGCC DAT
staining was primarily at the cell perimeter (Fig. 4A), although
some intracellular staining was apparent. Moreover, PKC
activation resulted in pronounced surface losses of EL2-CCPGCC
DAT, similar to that observed for wildtype and consistent with our
uptake results demonstrating functional downregulation of EL2-
CCPGCC DAT. We also expressed EL3, EL4 mutants and
visualized their cellular distribution. Neither EL3 nor EL4 were
present at the cell perimeter, and a diffuse perinuclear signal was
detected (Fig. 4B). These results are consistent with our uptake and
surface biotinylation results suggesting that EL3 and EL4 fail to
mature and traffic to the cell surface and that these mutations are
not well tolerated by DAT.
Discussion
In the current study, we aimed to introduce tetraCys residues in
DAT extracellular domains that intrinsically encode Pro-Gly
dipeptide sequences at DAT amino acid positions 194, 288 and
387. The CCPGCC sequence is the optimal sequence to facilitate
biarsenic dye binding, and once bound confers the proper dye
conformation for fluorescence emission [19], [21]. Converting the
four residues flanking the Pro-Gly at amino acid positions 194–195
yielded a DAT that retained DAT surface expression comparable
to wildtype. Moreover, EL2-CCPGCC DAT exhibit robust DA
uptake, albeit somewhat reduced as compared to wildtype, and
retained sensitivity to PKC-mediated downregulation, suggesting
that this mutant may be amenable to labeling with biarsenic dyes
for live imaging studies of DAT trafficking. A recent study
indicated that inserting a tetraCys motif at the DAT amino
terminus and at position 511 were also well tolerated [26].
However, these are both located on intracellular domains that
would require use of a membrane permeant biarsenic dye that
would have access to the entire cellular DAT population and
would not exclusively label the DAT surface residents. It is also
interesting to note that although we reproducibly observe PKC-
mediated DAT downregulation in PC12 cells, a recent study by
Ericksen et al reports lack of PKC-mediated downregulation in
primary ventral midbrain neurons prepared from P2 rat pups [16].
This conflicts with previous studies that report PKC-mediated
DAT downregulation in adult rat striatal synaptosomes [27], and
suggests that either the developmental stage of the dopaminergic
neuron or the primary culture environment may influence the
ability of DAT to undergo PKC-mediated downregulation.
While our data demonstrate that an extracellular tetracysteine-
tag is well tolerated by DAT, they do not demonstrate whether this
DAT construct can be labeled with biarsenic dyes. We made
several attempts to label EL2-CCPGCC DAT using Lumio brand
(Invitrogen) FlAsH reagent, using both standard approaches as
well as modified protocols that use extended washes with BAL
reagent to reduce non-specific FlAsH binding. All of our labeling
attempts resulted in a high degree of non-specific labeling of non-
transfected cells, as well as cells expressing either wildtype or EL2-
CCPGCC DAT (not shown). Problems with non-specific FlAsH
binding have been described [28], [29] and particular issues have
been raised regarding the utility and specificity of the commer-
cially available Lumio form of FlAsH [30]. Thus, while our EL2-
Figure 3. The presence of a tetracysteine in DAT EL2 does not
alter DAT maturation or surface expression. Surface biotinylation
assay. Cells were transfected with the indicated DAT constructs and cell
surface proteins were biotinylated and isolated from intracellular
proteins as described in Methods. A. Representative immunoblot
displaying surface (S) and intracellular (I) wildtype and EL2-CCPGCC
DAT. Mature (90 kDa) and immature (56 kDa) species are indicated. B.
Averaged data. Data are expressed as %total mature DAT on cell surface
6S.E.M. (n = 4). C. Representative immunoblot displaying surface (S)
and intracellular (I) EL3-CCPGCC and EL4-CCPGCC DAT. Total lysates are
displayed in the far right hand lanes. Note that no mature protein is
detected. Immature species (56 kDa) are indicated.
doi:10.1371/journal.pone.0009113.g003
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CCPGCC DAT is a viable DAT form, advances in FlAsH labeling
may be required in order to determine the utility of this mutant in
future trafficking studies.
DAT residues 192–197 are located between the second and
third glycosylation sites of the large second extracellular loop of the
protein. This region appears to tolerate amino acid substitution
well, as previous studies reported that an extracellular HA epitope
was successfully engineered across residues 193–203 [31]. The HA
epitope at this locus is accessible for extracellular antibody
labeling, suggesting that the much smaller biarsenic dye would
also have access to this DAT region. Cysteine conversion of EL3
and EL4 residues flanking the Pro-Gly at positions 288–289 and
387–388, respectively, yielded CCPGCC DAT mutants that were
not highly functional. Interestingly, a previous mutagenesis study
in which a cysteine-depleted DAT was generated indicated that
mutating an existing cysteine in EL3 at position 306, just
downstream of the EL3-CCPGCC DAT, resulted in the
expression of mature DAT protein [32] that is fully functional
[33]. Cys306 is positioned close to the sixth transmembrane
segment, suggesting that this region may be more tolerable to
structural perturbation.
In summary, we have characterized a functional DAT mutant
that encodes a tetraCys motif on the extracellular DAT domain
EL2. The ability to introduce cysteines at this locus may have
future utility both for NTSEA reagent labeling, as well as for
biarsenic dye labeling for live imaging studies. Future studies will
directly examine the capacity of this mutant to bind to biarsenic
dyes.
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Figure 4. Cellular distribution of tetracysteine mutant DATs. EL2-CCPGCC DAT is robustly expressed at the cell surface and internalizes in
response to PKC activation. Immunofluorescence microscopy. Cells were transfected with the indicated constructs and were fixed and stained with rat
anti-DAT antibodies as described in Methods. A representative panel of deconvolved images is presented. A single plane through each cell center is
shown. A. Effect of PKC activation on EL2-CCPGCC DAT. Prior to fixation, cells were treated with either vehicle or 1 mM PMA (37uC, 30 min). B. Cellular
distribution of EL3-CCPGCC and EL4-CCPGCC DAT. Note the lack of either protein at the cell surface.
doi:10.1371/journal.pone.0009113.g004
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